The National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) registries have been a source of biospecimens for cancer research for decades. Recently, registry-based biospecimen studies have become more practical, with the expansion of electronic networks for pathology and medical record reporting. Formalin-fixed paraffin-embedded specimens are now used for next-generation sequencing and other molecular techniques. These developments create new opportunities for SEER biospecimen research. We evaluated 31 research articles published during 2005 to 2013 based on authors' confirmation that these studies involved linkage of SEER data to biospecimens. Rather than providing an exhaustive review of all possible articles, our intent was to indicate the breadth of research made possible by such a resource. We also summarize responses to a 2012 questionnaire that was broadly distributed to the NCI intra-and extramural biospecimen research community. This included responses from 30 investigators who had used SEER biospecimens in their research. The survey was not intended to be a systematic sample, but instead to provide anecdotal insight on strengths, limitations, and the future of SEER biospecimen research. Identified strengths of this research resource include biospecimen availability, cost, and annotation of data, including demographic information, stage, and survival. Shortcomings include limited annotation of clinical attributes such as detailed chemotherapy history and recurrence, and timeliness of turnaround following biospecimen requests. A review of selected SEER biospecimen articles, investigator feedback, and technological advances reinforced our view that SEER biospecimen resources should be developed. This would advance cancer biology, etiology, and personalized therapy research.
Introduction
The Surveillance, Epidemiology, and End Results (SEER) Program, funded by the National Cancer Institute (NCI) since 1973, collects data from 20 cancer registries that cover 28% of the U.S. population to monitor cancer incidence and survival in the population and advance cancer surveillance research. As an expansion of biospecimen research, in 2001 SEER launched the Residual Tissue Repository (RTR) resource in Hawaii, Iowa, and Los Angeles to obtain formalin-fixed paraffin-embedded (FFPE) tissues before laboratories discarded them (1) . The RTR has supported research on prognostic and predictive biomarkers of cancer development and progression with de-identified cancer tissue samples linked to SEER demographic data, including race and age, and clinical data such as stage, treatment, and survival. With approximately 450,000 cancer diagnoses reported annually, SEER biospecimens have potential to serve as a resource for unbiased population-based studies, even of rare cancer histologies.
Advances in biomedical science and medical reporting during the past decade offer new opportunities for SEERlinked biobanking. Advances in electronic networks enable linkage of medical records to surgical or biopsy biospecimens (2) . De-identified data linkages to sources of clinical data such as Medicare claims (3) permit rich annotation of biospecimens (4) . Next-generation sequencing and other advances in molecular biology now allow FFPE tissues to be used for molecular analyses (5) , including studies of DNA methylation (6) and miRNA expression (7) in cancer. These developments create an opportunity for SEER registries to be a resource for acquisition of annotated biospecimens. A need exists for custom annotation of data, including chemotherapy history and recurrence, to support current research hypotheses.
Materials and Methods
This commentary includes a review of 31 selected original research articles published during 2005 to 2013 that linked SEER data to biospecimens. Articles were selected after obtaining authors' confirmation that biospecimens were linked to SEER data in these articles. The articles illustrate the breadth of research that SEER biospecimens already support. A summary of responses to an October 2012 questionnaire from cancer biospecimen researchers also is presented. Researchers were asked about their awareness of the SEER RTR and its strengths, limitations, and future directions. The results of the review of research articles and the survey suggest that further refinement and development of SEER biospecimen resources is warranted.
Results

Published research
Selection and characteristics. We evaluated 31 original research articles published during 2005 to 2013. Articles were selected on the basis of the authors' confirmation that cancer biospecimens were linked to SEER data in the studies. Research topics addressed in these SEER biospecimen research articles included cancer classification, epidemiology, and therapeutic targets. Table 1 summarizes aspects of these articles, including cancer and biospecimen type, research focus, and patient demographics.
Cancer type. Many studies examined SEER-linked biospecimens for the leading malignant cancer diagnoses: female breast (9, 23, 24, 27, 32, 37) , colon and rectum (18, 29, 30, 38) , lung (10) , and prostate (16) cancers. Other studies focused on cancer types responsible for an increasing proportion of cancer-related deaths, including pancreas (8, 21, 35, 36) and liver cancer (19, 22, 33) . Other cancer types of interest were lymphomas (11-13, 26, 28) ; cancers of the ovaries (25) , oral cavity, and pharynx (14, 31) ; and cervical cancer (20) . Although rare, vulvar (15, 17) and anal (34) cancer biospecimen collections could be assembled from across multiple registries.
Biospecimens. The principal biospecimen type at the registries was FFPE tissues (10-17, 19, 20, 23, 25, 27-31, 34, 37, 38) . FFPE cores also were used to construct tissue microarrays (TMA; refs. 8, 9, 18, 21, 22, 24, 32, 35, 36) and multiple tumor block arrays (26, 28) . In one study, FFPE tissues were used for pathology review, and frozen normal tissues were used for DNA methylation studies (33) . The most common source of biospecimens was a physical repository colocated with the registry (8-15, 17-19, 21-30, 32, 34-38) ; however, biospecimens maintained in pathology laboratories distributed across registry catchment areas also were used in many studies (16, 17, 20, 29-31, 33, 34) .
Biomarkers Biospecimen research topics (Table 1 ) included assessment of immunohistochemical markers (8, 9, 18, 21-23, 30, 32, 35, 36) and genetic sequences (10-17, 19, 20, 26, 28, 29, 31, 34) . Several studies examined histopathology markers (24, 25, 27, 37) and DNA methylation in cancer tissue (33, 38) .
Demographics. Several studies reported cancer subtype distributions across racial and ethnic populations (9, 12-14, 17, 18, 20-22, 24, 26, 35-38) . Biospecimens also were used to study molecular subtype distributions in the populations for cancer of the breast (9) and colon and rectum (30) , and for non-Hodgkin lymphoma (11) (12) (13) , including subtypes of diffuse large B-cell lymphoma (28) and Burkitt lymphoma (26) . One publication leveraged the population-based characteristics of SEER RTR biospecimens to project the increase in future oropharyngeal cancer incidence due to human papillomavirus (HPV) infection (14) . Another study reported HPV genotype distribution among vulvar cancer cases in 39 countries (15) . Both of these HPV-related articles addressed the implications of their findings for ongoing HPV vaccination efforts. Table 2 summarizes additional aspects of selected SEER biospecimen articles, including study purpose, risk factors of interest, participating SEER registries, and sources of funding.
Study purpose. One common research topic addressed in the SEER biospecimen research articles was cancer etiology (10-15, 17, 19-20, 24, 26-29, 31, 33, 34, 37, 38) . Several studies used SEER survival data to assess the prognostic value of biomarkers (8, 11, 14, 21-23, 35, 36) . In other instances, biospecimens were used to evaluate biomarkers that potentially were associated with the detection, development, and progression of malignancy (16, 18, 24, 33, 37, 38) .
Risk factors. SEER-linked biospecimens were used in studies of risk factors associated with cancer. Although the majority of studies used de-identified linked data, several studies obtained patient consent to link their biospecimens to questionnaire responses (10-13, 24, 27, 29, 33, 37, 38) . A range of exposures were examined. These included studies of HPV in head and neck (14, 31) and anogenital cancer cases (15, 17, 20, 34) . Detroit registry researchers studied relationships between HPV genotypes in oropharyngeal cancers and area-level smoking data (31) . Two other studies, of lung (10) and colorectal cancer (29) , respectively, included individual data on tobacco use. Two studies tested hepatocellular carcinoma tumor blocks for the presence of Hepatitis B and C viruses (19, 33) . The Iowa registry participated in studies of agricultural exposures associated with non-Hodgkin lymphoma (12, 13) . Other exposures of interest were radon (10), soy intake (24), Epstein-Barr virus infection (26) , parity (27) , HIV infection (28), alcohol use (33), mammographic tissue density (37) , and menopausal hormone therapy (38) .
Registries. Residual biospecimens were acquired from the SEER RTR in Hawaii (8, 9, 14, 15, 17-22, 24-27, 32-37), Iowa (8, 10-17, 20, 21, 23, 25, 26, 29, 30, 34-36) , and Los Angeles (8, 11, 13, 14, 17, 20, 21, 25, 26, 28, (34) (35) (36) 38) . In some instances, biospecimen collection was supplemented to include tissues retrieved from pathology laboratories. SEER registries in Seattle, Detroit, Kentucky, and Louisiana also contributed biospecimens (11, 13, 17, 20, 31, 34) . Other studies were collaborations between SEER and other registries (10, 12, 17, 20, 34) .
Funding. SEER contracts were a major source of funding for RTR-based studies (32) (33) (34) (35) (36) (37) (38) 
Biospecimen Researcher Questionnaire
Questionnaire
After Office of Management and Budget clearance was obtained, a Web-based questionnaire was distributed by NCI to investigators with a known interest in biospecimen research. Responses were provided during October 2012. The goal was to assess awareness of the RTR, views on its strengths and limitations, and recommendations on the future direction of SEER biospecimen efforts. NCI's Surveillance Research Program sent an email invitation to 70 co-authors of articles that used SEER-linked biospecimens and investigators affiliated with the 20 SEER registries. NCI's Epidemiology and Genomics Research Program (EGRP) sent the invitation to investigator LISTSERV groups, including the American Association for Cancer Research Molecular Epidemiology Working Group, NCI Biospecimens, and the Division of Cancer Control and Population Sciences' Friends of EGRP. Recipients were asked to forward the email invitation to peers in the cancer research community. The online questionnaire was not intended to provide systematic information. Instead, anecdotal input from the research community was meant to provide insight on strengths, limitations, and the future of SEER biospecimen research. 
Questionnaire responses
The questionnaire included 10 questions (Table 3 ). The number of responses varied for each question.
Respondents' backgrounds. The majority of the 174 overall respondents (67%) were affiliated with academic institutions (Q1 ; Table 3A ). A total of 30 respondents indicated that they had accessed SEER biospecimens (Q2). Of 90 respondents who had not used the resource, 40% were waiting to obtain preliminary results or funding before applying, and the resource did not meet the needs of 31% (Q3). Some but not all of the 90 respondents continued with question 8, after skipping questions 4 to 7, which were directed at investigators who had used the SEER RTR.
Responses of SEER RTR researchers. Only investigators who indicated that they had used the RTR were asked questions 4 to 7 (Table 3B ). Among 26 RTR users who responded to the question about their research (Q4), interests included biomarker identification/validation (31%), whole-genome analysis (27%), multivariate molecular profiling (23%), and other uses (19%). Among 22 RTR users who answered whether or not the RTR met their needs, 19 (86%) indicated that the RTR meet their research needs (Q5). A total of 24 previous RTR researchers provided comments on the benefits of SEER RTR biospecimens (Q6a), which included population coverage (42%), the number of biospecimens available (29%), and cost (13%). Limitations listed by 22 previous users (Q6b) included sample size (36%), quality control documentation (36%), and incomplete clinical annotation (27%). In response to question 7, a total of 24 previous RTR investigators provided recommendations for improving access to SEER-linked biospecimens. Recommendations included increasing the number of biospecimens available (25%) and developing a more streamlined application process (21%).
Future SEER biospecimen resources. Forty-three investigators provided recommendations on the future direction of SEER biospecimen research (Q8 ; Table 3C ). Priorities included prognostic biomarker studies (33%), biomarker identification and validation (21%), and molecular profiling for the purpose of tumor classification (19%). Among 25 investigators who commented on tissue quality issues (Q9), efforts to ensure biospecimen quality control were seen as useful (64%), and integration of pathology review and more detailed annotation were both recommended (12%). Availability of agematched controls and adjacent normal tissue were additional recommended enhancements. More than one response could be selected for question 10, pertaining to annotation needs, and a total of 70 responses were provided. In descending frequency, researchers listed these items as very important: tissue collection, processing, and storage conditions (58% of researchers); type of treatment received (56% of researchers); age of biospecimen (52% of researchers); risk factors associated with cancer diagnoses (42% of researchers); and type of health insurance (4% of researchers).
Discussion
A review of a selection of SEER registry-based biospecimen articles demonstrates the breadth of research that this resource can support. Innovations in molecular biology are expanding the potential value of FFPE biospecimens as a resource for biomedical research. Advances in electronic medical record reporting also can assist registries in locating and annotating tissues that meet study criteria. Although fresh-frozen tissue collections are a gold standard for preserving nucleic acids and proteins, the expense of procurement and maintenance may not be feasible in many clinical or research settings. Fortunately, methods of nucleic acid and protein analysis using FFPE samples have advanced rapidly, expanding their potential for research on the molecular mechanisms of cancer (39) , including miRNA profiles (40, 41) , genome-wide analysis of copy number and mutations (42) , wholegenome methylation (6), other epigenetic markers (43) , and proteomic studies with FFPE samples (44, 45) . Thus, FFPE biospecimens, drawn from unbiased SEER catchments, hold promise for cancer research. The potential to annotate these biospecimens with detailed demographic and clinical data from electronic records is another compelling aspect of performing biospecimen research using data from SEER registries.
On the basis of anecdotal information gained from the investigator questionnaire, several key goals were identified for future registry-based biospecimen research. These include implementation of an efficient, centralized process with consistent methods for tissue acquisition to support hypothesis-driven biospecimen research. Linkage to external data sources would enhance biospecimen annotation with detailed information on risk factors, comorbidities, and treatment. The use of SEER-linked biospecimens could be an efficient mechanism to reduce research costs by assisting in case ascertainment, biospecimen acquisition, annotation, and follow-up of vital status. To realize this goal, Institutional Review Board (IRB) and material transfer agreement (MTA) processes should be simplified and expedited to the extent possible. In this way, SEER biospecimen processes could increase sample size, statistical power, and diligent completion of biospecimen acquisition for case-only, case-control, and cohort studies, as well as clinical trials.
A combination of centralized processes and dedicated registry staff is recommended to facilitate SEER multiregistry biospecimen activities. Central coordination processes can help to locate and coordinate acquisition of biospecimens that meet specific study criteria. Dedicated personnel at the registry level are essential to developing trusting relationships between collaborating pathology laboratories to retrieve, annotate, and transfer biospecimens to investigators. Ethical issues involving informed consent should be addressed to make these processes run smoothly. The engaged support of registries, medical facilities, providers, patients, and community advocates will be essential for this large-scale, population-based biospecimen resource to be successful (46) . In summary, registry-linked biospecimens hold promise as a resource for cancer research. Carefully developing this resource is a priority of NCI's SEER cancer registry program.
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